Myb overexpression overrides androgen depletion–induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance

Sanjeev K.Srivastava1, Arun Bhardwaj1, Seema Singh1, Sunnit Arora1, Steven McClellan1, William E.Grizzle2, Eddie Reed1 and Ajay P.Singh1,3,

1Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36604-1405, USA
2Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA and 3Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA

© The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Introduction

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths in men in the USA (1). Effective treatment of early-stage localized disease involves surgery (radical prostatectomy) or radiation therapy, whereas androgen deprivation therapy is the first line of intervention for advanced metastatic disease. However, after an initial clinical response, prostate tumors relapse in majority of cases as androgen deprivation- or castration-resistant tumors, resulting in poor prognosis (2). Such a transition has been attributed to a variety of mechanisms that include AR overexpression, ligand-independent activation and other AR-independent mechanisms (3–6). Indeed, the development of prostate cancer and subsequent progression to castration resistance is a complex process that may involve multiple genetic and epigenetic changes promoting proliferation, survival and aggressive behavior of prostate cancer cells (7).

Abbreviations: EMT, epithelial to mesenchymal transition; PSA, prostate-specific antigen.

In an earlier study, Myb was identified among the genes that are amplified at higher frequency in hormone-refractory prostate cancer (8). Myb, also referred as c-Myb, is the cellular progenitor of the v-Myb oncogenes carried by the chicken retroviruses AMV and E26 that cause acute myeloblastic leukemia or erythroleukosis (9). Myb encodes for a transcription factor, which activates gene expression in most cases by binding to the responsive promoter regions, the Myb binding sites. In some cases, activation by Myb can also occur independent of its DNA binding (10). Earlier reports suggested a restricted expression of Myb in the immature hematopoietic cells of all lineages, which decreased as the cells differentiated (11). Later on, Myb expression was also reported in other tissues as well as in hematological and other solid malignancies (12–15). Functional studies in hematopoietic cells have suggested that Myb plays a role in maintaining the undifferentiated proliferative state of immature cells (16). Myb-knockout mice died at embryonic stage and exhibited an essential defect of normal hematopoiesis (17). Studies have shown that Myb activity is essential for continued proliferation and survival of acute and chronic myeloid leukemias (AML and CML) (18,19) and reduced Myb levels can, in fact, impair the transformation by other leukemogenic oncogenes (18,20). Myb confers its oncogenic activity by regulating the expression of a wide array of target genes and a pathogenic role of Myb has also been suggested in melanoma, head and neck, breast and colon cancers (21–23).

Here, we report an extensive study demonstrating the functional significance of Myb in prostate cancer. Using both gain and loss of function approaches, we show that Myb promotes growth and androgen deprivation–resistance of prostate cancer cells and confers aggressive phenotype by facilitating epithelial to mesenchymal transition (EMT).

Materials and methods

Cell culture

LNCaP, DU145, PC3 (ATCC, Rockville, MD) and C4-2 (UroCor, Oklahoma City, OK) cell lines were maintained in RPMI 1640 media (Invitrogen, Carlsbad, CA) supplemented with 5.0% fetal bovine serum and 100 μg/ml penicillin and streptomycin (Invitrogen). RWPE1 and RWPE2 (ATCC) were maintained in keratinocyte serum free medium (Gelantis, San Diego, CA) plus 5 ng/ml epidermal growth factor. All cell lines were cultured in humidified atmosphere supplemented with 5% CO2 and media was replaced every alternate day. Short tandem repeats genotyping and intermittent testing for androgen deprivation (5 ng/ml; for overexpression) or Puromycin (2 µg/ml; for knockdown) were used as a way to authenticate the cell lines.

Constructs, transfections and treatments

Short hairpin RNA expression constructs for Myb (pGFP-V-RS-shMyb) and scrambled control (pGFP-V-RS-Scr) were purchased from Origene (Rockville, MD). A Myb overexpression construct was generated through subcloning of Myb insert from pCMV6-XL5-Myb plasmid (Origene) into pCMV6-NEO vector (Origene). For ectopic Myb overexpression and knockdown, LNCaP and C4-2 cell lines were transfected with pCMV6-Myb and pGFP-V-RS-shMyb, respectively, along with respective control plasmids, using FuGENE as a transfection reagent as per the manufacturer’s instructions. Stable pooled population of transfected cells were selected in RPMI-media containing 4 mg/ml G418 (200 µg/ml; for overexpression) or Puromycin (2 µg/ml; for sh hairpin RNA), expanded and examined for stable Myb overexpression or silencing. To assess androgen deprivation–resistance, cells were grown in culture media supplemented with 5% charcoal-stripped serum (steroid-reduced) (Gemini Bio-Products, West Sacramento, CA).

RNA isolation and reverse transcription polymerase chain reaction

Total RNA was isolated using RNAeasy Purification Kit (Qiagen, Maryland) and reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) following manufacturer’s instructions.
Quantitative real-time PCR was performed in 96-well plates using SYBRGreen Master Mix (Applied Biosystems, Warrington, UK) on an iCycler system (Bio-Rad, Hercules, CA). The following PCR primer pairs were used: Myb forward (5'-TCAGGAACCTTTCTCTGACA-3') and reverse (5'-GGCTGGTGCAGAAAGGCAAG) and Glyceraldehyde 3-phosphate dehydrogenase forward (5'-GAGTCCGTTGGTCTGGAAGAT-3') and reverse (5'-GTTGGGTCCTGGAAGAT-3'). The thermal conditions for real-time PCR assays were as follows: cycle 1: 95°C for 10 min, cycle 2 (x40): 95°C for 10 s and 60°C for 45 s.

**Western blot analysis**

Cells were processed for protein extraction and western blotting as described earlier (24). Immunodetection was carried out using specific antibodies against: Myb, prostate-specific antigen (PSA), AR and Vimentin (all rabbit monoclonal) (Epitomics, Burlingame, CA), Slug, Snail, BAD, Bcl-xL (all rabbit monoclonal), Bax (rabbit polyclonal) (Cell Signaling Technology, Beverly, MA), E-cadherin and N-cadherin (mouse monoclonal) (BD transduction laboratories, Bedford, MA), p21 (mouse monoclonal), p27, Cyclin A1, Cyclin D1, Cyclin E1, Twist (all rabbit polyclonal) (Santa Cruz Biotechnology, Santa Cruz, CA) and β-actin (mouse monoclonal) (Sigma–Aldrich, St Louis MO). All secondary antibodies (Santa Cruz) were used at 1:2500 dilutions. Blots were processed with ECL plus Western Blotting detection kit (Thermo Scientific, Logan, UT) and the signal detected using an LAS-3000 image analyzer (Fuji Photo Film Co., Tokyo, Japan).

**Immunofluorescence assay**

Cells were grown at low density on sterilized coverslips, washed with 0.1 mol/l HEPES containing Hanks' buffer and fixed in ice-cold methanol at −20°C for 2 min. After nonspecific blocking with 10% goat serum containing 0.05% Tween 20 for at least 30 min, cells were incubated with anti-Myb rabbit monoclonal antibody in PBS (1:100) for 90 min at room temperature followed by washing. Cells were then incubated with TRITC-conjugated goat anti-rabbit secondary antibodies (Santa Cruz) for 60 min and after washing, the coverslips were mounted on glass slides in antifade Vectashield mounting medium (Vector Laboratories, Burlingame, CA). For actin filament staining, cells grown on glass coverslips were fixed with 4% formaldehyde in PBS for 10 min at room temperature. The fixed cells were washed with PBS and permeabilized with 0.2% Triton X-100 in PBS for 5 min. After washing, the cells were stained with Alexafluor 488 phalloidin (Molecular Probes, Invitrogen, Eugene, OR) for 20 min, washed twice with PBS-Tween 20 and mounted on glass slides in antifade Vectashield mounting medium. Immunostaining was observed under Nikon Eclipse TE2000-U fluorescence microscope (Nikon Instruments, Melville, NY).

**Growth kinetics assay**

Cells (1 × 10⁴/well) were seeded in triplicate in 6-well plates and allowed to grow for different time intervals. The growth rate was determined by counting the number of cells on a hemocytometer, every day for 8 days. Cell population doubling time (T_D) was calculated during exponential growth phase (96–144 h) using the following formula: T_D = 0.693 t /ln (Nt/N0), where t is time (in h), Nt is the cell number at time t, and N0 is the cell number at initial time (25).

**Soft-agar colony formation and plating efficiency assay**

Equal volumes of agarose (1.6%) and growth medium were mixed and plated to form bottom layer (0.8% agar growth medium) in 6-well plates. Cells (2.5 × 10⁶ cells/ml) were suspended in regular media, mixed with equal volume of 0.6% agarose and cell suspension-agar mix (2 ml) seeded as top layer in each well. Plates were incubated under normal culture conditions for 3 weeks for colony formation. Colonies were stained with 0.025% crystal violet (Sigma–Aldrich) in PBS, observed using Nikon Eclipse microscope (Nikon Instruments) and counted in ten randomly selected fields (×100 magnification). For plating efficiency, single cell suspensions were plated in 6-well plates at a density of 2.5 × 10⁵ cells/well in complete or steroid-reduced media for colony formation. After 2 weeks, colonies were fixed with methanol, stained with crystal violet, photographed and counted using Image analysis software (Gene Tools, Syngene, Frederick, MD).

**Cell cycle analysis**

Cells were synchronized by culturing them in serum-free media for 72 h and then incubated in either regular or steroid-reduced media for 24 h. After washing and trypsinization, cells were fixed with 70% ethanol overnight at 4°C, washed with cold PBS and stained with propidium iodide using PI/RNase staining buffer for 1 h at 37°C. Stained cells were analyzed by flow-cytometry on a BD-FACS Canto™ II (Becton–Dickinson, San Jose, CA). The percentage of cell population in various phases of cell cycle was calculated using Mod Fit LT software (Verity Software House, Topsham, ME).

**Apoptosis assay**

Apoptosis was measured by using the PE Annexin V apoptosis detection kit (BD Biosciences, San Diego, CA). The cells were grown in steroid-supplemented (fetal bovine serum) or -reduced (charcoal-stripped serum) condition for 96 h. Apoptosis was detected by staining the cells with PE Annexin V and 7AAD solution followed by flow cytometry.

**Motility and invasion assays**

For motility assay, cells (2 × 10⁵) were plated in the top chamber of non-coated polyethylene teraphthalate membrane (6-well inserts, pore size 8 μm; BD Biosciences). For the invasion assay, 5 × 10⁴ cells were plated in the top chamber of the transwell with a Matrigel-coated polycarbonate membrane (24-well inserts 0.8 μm, BD Biosciences). RPMI-1640 medium with 10% fetal bovine serum was added to the lower chamber as a chemoattractant. After 16 h of incubation, cells remaining on the upper surface of the insert membrane were removed by cotton swab. Cells that had migrated or invaded through the membrane/Matrigel to the bottom of the insert were fixed and stained with Diff-Quick cell staining kit (Dade Behring, Newark, DE) and mounted on slide.

**Aggregation assay**

Cells were tested for their ability to aggregate in hanging drop suspension cultures as previously demonstrated (25). In brief, drops of cell suspension (20 μl each containing 20 000 cells) were placed onto the inner surface of the lid of a Petri dish. The lid was then placed on the Petri dish so that the drops were hanging from the lid with the cells suspended within them. After overnight incubation at 37°C, the lid of the Petri dish was inverted and photographed using Nikon Eclipse microscope (Nikon Instruments).

**Results**

Myb is overexpressed and associated with enhanced growth and clonogenicity in prostate cancer cells

We observed an aberrant expression of Myb in all the prostate cancer cell lines (LNCaP, C4-2, DU145 and PC3), whereas no or negligible expression was noted in prostate epithelial cell lines (RWPE1 and RWPE2) (Figure 1A). Notably, Myb expression was significantly greater (p < 0.05) in all the castration-resistant (CR: C4-2, PC3 and DU145) cells as compared with androgen-dependent (AD: LNCaP) prostate cancer cells. Highest level of Myb expression was observed in CR C4-2 cells, which exhibited more than 60- and 15-folds increase at mRNA (Figure 1A, upper panel) and protein levels (Figure 1A, lower panel), respectively, as compared with its parental AD LNCaP cells. Immunofluorescence analysis demonstrated an intense staining of Myb in C4-2 cells, which was predominantly localized in the nucleus with some low diffuse staining in the cytoplasm (Figure 1B).

For functional analysis, Myb-overexpressing (LNCaP-Myb) or knockdown (C4-2-shMyb) stable sublines were generated along with their control transfectants (LNCaP-Neo and C4-2-Scr) and characterized for Myb overexpression or silencing (Figure 1C). We next examined the effect of Myb modulation on growth and clonogenicity of LNCaP and C4-2 cells, respectively. Our data demonstrated that overexpression of Myb in LNCaP cells significantly enhanced their growth rate, whereas it decreased in Myb-silenced C4-2 cells as compared with their respective control cells (Figure 1D). The total number of LNCaP-Myb cells on 8th day of culture indicated 29.4% increase in growth as compared with LNCaP-Neo cells, whereas 37.6% growth inhibition was observed in Myb-silenced C4-2-shMyb cells relative to C4-2-Scr cells (Figure 1D). Growth analysis during exponential phase (96–144 h) demonstrated a decrease in population doubling time of LNCaP-Myb (37.6 h) cells as compared with LNCaP-Neo (45.5 h) cells, whereas C4-2-shMyb cells exhibited an increase (30.2 h) compared with C4-2-Scr (26.4 h) cells. In an anchorage-independent clonogenicity assay, LNCaP-Myb cells showed ~4.98-fold enhanced clonogenic ability as compared with LNCaP-Neo cells. In accordance with this data, clonogenicity was decreased by ~2.4-fold in Myb-overexpressing C4-2-shMyb cells as compared with the C4-2-Scr cells (Figure 1E). Altogether, our findings demonstrate a role of Myb in potentiating growth and clonogenicity of prostate cancer cells.
Overexpression of Myb supports androgen deprivation–resistant growth of prostate cancer cells and upregulates PSA expression

Considering enhanced amplification frequency (8) and observed overexpression of Myb in CR prostate cancer cells, we sought out to investigate its role in androgen deprivation–resistance. For this, we analyzed the plating efficiency (an ideal test to monitor growth in long-term) of Myb-overexpressing and -knockdown cells under steroid-supplemented and -reduced conditions. Our data showed an increased (~2.05-fold) plating efficiency in LNCaP-Myb cells as compared with LNCaP-Neo cells under steroid-supplemented conditions (Figure 2A). Similarly, C4-2-Scr cells also exhibited greater (~1.79-fold) plating efficiency as compared with Myb-silenced C4-2 cells. Notably, when the plating efficiency was examined under steroid-deprived condition, a >12-fold reduction was observed in LNCaP-Neo cells, whereas it only decreased to ~4.0-fold in LNCaP-Myb cells as compared with that in steroid-supplemented condition (Figure 2A). Likewise, C4-2-Scr cells exhibited a 1.2-fold decrease under steroid-reduced condition, whereas it was reduced by 2.56-fold in C4-2-shMyb cells as compared with the plating efficiency in steroid-supplemented condition.
1.58-fold decrease was observed in LNCaP-Myb cells. Similarly, about a 3.5-fold decrease in the number of cells in S-phase, whereas only Myb (LNCaP-Myb, 41.19%; C4-2-Scr, 30.34%) cells as compared with low showed an enhanced fraction of cells in S-phase in steroid-supplemented and -depleted conditions. Our data on cell cycle cycle progression and apoptosis of prostate cancer cells under both (29). Therefore, we examined the effect of altered Myb expression on key proteins involved in cell proliferation and survival. Our data demonstrated an induced expression of cyclins (A1, D1 and E1) upon Myb overexpression in LNCaP cells, whereas it was decreased upon Myb silencing in C4-2 cells under both steroid-supplemented and -depleted conditions (Figure 4). In contrast, we observed a downregulation of p27/KIP1 (cyclin-dependent kinase inhibitor 1B) in Myb-overexpressing LNCaP, whereas it was upregulated in Myb-silenced C4-2 cells. Interestingly, a slight increase in the expression of another cyclin-dependent kinase inhibitor, p21/WAF1, was observed upon Myb overexpression in LNCaP cells, whereas it was decreased in Myb-silenced C4-2 cells. Among the survival proteins, the expression of both Bcl-xL and Bcl-2 was upregulated upon Myb overexpression in 1.98-fold decrease in the number of cells in S-phase was observed in low Myb-expressing C4-2-Scr cells, whereas it only decreased to 1.15-fold in C4-2-Scr cells upon steroid deprivation (Figure 3A).

We next examined the effect of Myb on apoptosis resistance of prostate cancer cells (Figure 3B). Our data indicated a lower apoptotic index (Annexin V positive/7AAD negative cells) in Myb-overexpressing LNCaP-Myb (23.7%) and C4-2-Scr (9.6%) cells as compared with low Myb-expressing LNCaP-Neo (34.4%) and C4-2-shMyb (20.2%) cells, respectively. Upon steroid deprivation, apoptotic indices increased considerably in both low and high Myb-expressing cells. However, greater increases (2.03- and 2.13-folds, respectively) were observed in low Myb-expressing C4-2-shMyb cells, whereas it only decreased to 1.98-fold in C4-2-Scr cells upon steroid deprivation (Figure 3A). Moreover, we observed a rebound of PSA is generally observed as the prostate cancer progresses to androgen deprivation–resistance (27,28). Interestingly, we also observed an elevated expression of PSA in Myb-overexpressing LNCaP cells, whereas it was reduced in Myb-silenced C4-2 cells as compared with their respective controls (Figure 2B). Furthermore, under steroid-reduced condition, PSA expression reduced considerably in low Myb-expressing (LNCaP-Neo and C4-2-shMyb) cells, whereas it was fairly sustained in Myb-overexpressing (LNCaP-Myb and C4-2-Scr) prostate cancer cells. Notably, while AR expression reduction considerably upon steroid deprivation, no change was observed in Myb-overexpressing or -silenced cells as compared with their respective controls (Figure 2B). Altogether, our data suggest that Myb overexpression supports androgen deprivation–resistant growth and is associated with elevated expression of PSA in prostate cancer cells.

**Modulation of myb expression alters the expression of cell cycle- and survival-associated proteins**

Having observed a role of Myb in cell cycle progression and resistance to apoptosis, we next examined the effect of altered Myb expression on key proteins involved in cell proliferation and survival. Our data demonstrated an induced expression of cyclins (A1, D1 and E1) upon Myb overexpression in LNCaP cells, whereas it was decreased upon Myb silencing in C4-2 cells under both steroid-supplemented and -depleted conditions (Figure 4). In contrast, we observed a downregulation of p27/KIP1 (cyclin-dependent kinase inhibitor 1B) in Myb-overexpressing LNCaP, whereas it was upregulated in Myb-silenced C4-2 cells. Interestingly, a slight increase in the expression of another cyclin-dependent kinase inhibitor, p21/WAF1, was observed upon Myb overexpression in LNCaP cells, whereas it was decreased in Myb-silenced C4-2 cells. Among the survival proteins, the expression of both Bcl-xL and Bcl-2 was upregulated upon Myb overexpression in Myb promotes cell cycle progression and confers apoptosis resistance to prostate cancer cells

Growth suppression in androgen-dependent prostate cancer cells upon androgen ablation is associated with cell cycle arrest and induction of apoptosis, whereas castration-resistant cancer cells have developed mechanisms to sustain their growth under steroid-reduced condition (29). Therefore, we examined the effect of Myb expression on cell cycle progression and apoptosis of prostate cancer cells under both steroid-supplemented and -depleted conditions. Our data on cell cycle showed an enhanced fraction of cells in S-phase in Myb-overexpressing (LNCaP-Myb, 41.19%; C4-2-Scr, 30.34%) cells as compared with low Myb-expressing (LNCaP-Neo, 28.27%; C4-2-shMyb, 20.63%) cells (Figure 3A). Upon steroid depletion, LNCaP-Neo cells exhibited a 3.5-fold decrease in the number of cells in S-phase, whereas only a 1.58-fold decrease was observed in LNCaP-Myb cells. Similarly, about...
Myb overexpression in prostate cancer

LNCaP cells, whereas it was downregulated in Myb-knockdown C4-2 cells. Likewise, we observed a decrease in the expression of pro-apoptotic Bax protein in Myb-overexpressing LNCaP cells and it was upregulated in Myb-silenced C4-2 cells. No change, however, was observed in the expression of another pro-apoptotic protein, BAD, in either Myb-overexpressing or -silenced cells (Figure 4).

Myb overexpression promotes cell motility and invasion and diminishes cell–cell interaction

As progression to castration resistance is associated with increased aggressiveness (30), we investigated a role of Myb in promoting the malignant behavior of prostate cancer cells. First, we studied the effect of altered Myb expression on motility and invasiveness, which are important characteristics of the aggressive cancer cells. Our data showed that there was a 2.7-fold increase in the motility of LNCaP cells upon Myb overexpression, whereas a 5.0-fold decrease was observed in Myb-knockdown C4-2 cells as compared with their respective controls (Figure 5A). We also observed that LNCaP-Myb cells were more (3.2-fold) invasive as compared with the LNCaP-Neo cells, whereas C4-2-shMyb cells exhibited decreased (5.4-fold) invasiveness as compared with C4-2-Scr cells (Figure 5B). As malignant cells tend to lose cell–cell interaction during progression toward...
more aggressive and metastatic phenotype, we examined the effect of Myb on prostate cancer cells in a cell aggregation assay. Our data showed a decreased cell–cell interaction in Myb-overexpressing LNCaP cells, whereas it was increased in Myb-silenced C4-2 cells as compared with their respective controls (Figure 5C). Altogether, our data indicate that Myb overexpression is associated with aggressive behavior of the prostate cancer cells.

**Myb overexpression favors epithelial to mesenchymal transition of prostate cancer cells**

Cancer cells gain mesenchymal features during their progression, a process referred to as epithelial to mesenchymal transition (EMT) (31). Mesenchymal cells are relatively more motile and exhibit less cell–cell communication; therefore, we investigated whether Myb had a role in EMT of prostate cancer cells. Considering the fact that actin-dependent membrane protrusions serve as a critical determinant of EMT (32), we examined actin organization in Myb-overexpressing or -silenced prostate cancer cells. Staining of filamentous-actin with FITC-conjugated phallolidin revealed the presence of many filopodial structures in Myb-overexpressing (LNCaP-Myb and C4-2-Scr) cells, whereas they were absent or less obvious in the low Myb-expressing (LNCaP-Neo and C4-2-shMyb) cells (Figure 6A). We next studied the expression of a series of EMT marker proteins in Myb-overexpressing or -silenced prostate cancer cells. Our data demonstrated decreased expression of epithelial (E-cadherin) and increased expression of mesenchymal markers (N-cadherin, Vimentin, Slug, Snail and Twist) in Myb-overexpressing (LNCaP-Myb and C4-2-Scr) cells as compared with low Myb-expressing (LNCaP-Neo and C4-2-shMyb) cells (Figure 6B). These findings support a role of Myb in favoring EMT of prostate cancer cells.

**Discussion**

Myb is a transcription factor known to regulate the expression of several genes that play crucial roles during cellular proliferation, differentiation and survival (9). Its role has also been demonstrated in hematopoietic and some solid malignancies along with a recent report associating its amplification with hormone-refractory prostate cancer (8,12–14). However, the contribution of Myb in the pathogenesis of prostate cancer has remained unexplored. The present study
Myb in prostate cancer. Our findings strongly support that Myb overexpression in prostate cancer due to gene amplification (and/or other yet unidentified mechanisms) may be one of the mechanisms potentiating prostate cancer growth, androgen deprivation-resistant progression and aggressive tumor phenotypes. This notion is based on (i) overexpression of Myb in prostate cancer cells with relatively greater expression in hormone-refractory cells, (ii) Myb-induced promotion of growth and clonogenicity of prostate cancer cells, (iii) Myb-supported androgen deprivation–resistance and induction of PSA expression, (iv) enhanced tumor motility and invasion, and loss of homotypic interaction of Myb-overexpressing tumor cells and (v) Myb-induced EMT. These findings underscore the significance of Myb as a novel molecular target in prostate cancer potentially controlling the progression to hormone therapy–resistant aggressive phenotypes.

Emergence of hormone-independent disease following androgen-deprivation therapy is a major clinical problem for the reason that the relapsed disease also does not respond well to alternative therapies (29). Therefore, characterization of Myb as a novel target promoting androgen deprivation–resistance and aggressiveness of prostate cancer cells is highly significant. Multiple mechanisms have been proposed for castration-resistant progression of prostate cancer (7). Considering the highly heterogeneous nature of this malignancy, it is possible that more than one mechanisms with unique or overlapping functions are operative. The data presented herein provide a mechanism in which Myb overexpression promotes androgen deprivation–resistance by sustaining cell cycle progression and preventing apoptosis under androgen-deprived condition. Importantly, our data also show an induced expression of PSA in Myb-overexpressing prostate cancer cells. This is of great significance, as PSA is an androgen-responsive gene and its serum levels are being used for prostate cancer screening and monitoring of the disease after androgen ablation therapy (27,28). It is believed that relapse of PSA after androgen-deprivation therapy is due to reactivation of AR signaling through AR overexpression, mutations, altered expression of AR coregulators, intracrine signaling, etc. (5,6,33). Nonetheless, in other reports, additional AR-independent mechanisms of PSA upregulation have also been suggested (34,35). As our data showed no noticeable change in AR expression upon Myb modulation, we propose that Myb either induces PSA expression in an AR-independent manner or sustain AR signaling through yet unidentified mechanisms. PSA promoter contains multiple Myb-binding sites (Singh, A.P., unpublished data), therefore, it is possible that Myb induces PSA expression through direct transcriptional upregulation. Alternatively, Myb may cooperate with AR to promote and sustain PSA expression under androgen-supplemented and -depleted conditions, respectively. In fact, it has been shown earlier that Myb cooperates with other transcription factors, such as C/EBP, Ets, CBF and PU.1 to regulate gene expression (36–38). Therefore, it will be of great interest to examine the combinatorial actions of Myb and AR in prostate cancer.

Normal cell growth is maintained and modulated by both proliferative and apoptotic signals and disruption of their balance contributes to the oncogenic process. It has been reported previously that androgen supports survival and proliferation of prostate cancer cells, and its ablation leads to cell cycle arrest and induction of apoptosis (29,39,40). During the castration-resistant progression, prostate cancer cells are able to bypass these growth checkpoints due to overexpression of cyclins and/or anti-apoptotic proteins and/or loss of cell cycle inhibitors and/or pro-apoptotic proteins (2,7). Data presented herein demonstrate that Myb overexpression induces the expression of cell cycle- and survival-associated proteins and is sufficient to sustain their levels under androgen-depleted condition to support cell growth. In corroboration with these observations, it has been reported earlier that Myb upregulates the expression of cyclin A1 in myeloid leukemia cells (41). A reduced expression of cyclin E1 is also reported in Myb-mutant mouse strains causing a proliferation defect (42). A significant overexpression of Bcl-xL was also observed in Myb-overexpressing colon cancer cells correlating with enhanced tumorigenicity in mice xenograft model (43). Myb is also shown to promote the survival of CD4+CD8+ double-positive thymocytes through upregulation of Bcl-xL (44). In other studies, an association of Bcl-2 with Myb has also been reported in T-lymphocytes (45), colon tissue (16), and cancer cells (23,46).

Our data also demonstrate a role of Myb in potentiating malignant behavior of prostate cancer cells and favoring EMT. This is highly significant considering the fact that the relapsed hormone-refractory cancers are also highly aggressive and more metastatic than the hormone-dependent disease (30). Myb has been shown previously to promote migration and invasion by direct or indirect mechanisms in smooth muscle and hepatocellular carcinoma cells (47,48). Furthermore, in two recent reports, a role of Myb in inducing EMT has also been demonstrated (49,50). In one study, it was shown that Myb acted downstream of BMP4 signaling cascade and its elevated expression cooperated with BMP4 to trigger EMT and migration of neural crest cells (50). The other study showed that Myb regulated the expression of Slug in tumor cells of different origin and altered the expression of a variety of epithelial and mesenchymal markers (49). Importantly, it was also shown that Myb-dependent Slug expression was essential for the homing of chronic myeloid leukemia K562 cells to the bone marrow (49). These observations together with our findings strongly support a role of Myb in aggressive behavior and metastasis of the cancer cells.

Fig. 6. Myb overexpression induces EMT. (A) Actin organization was examined as a measure of EMT in Myb-overexpressing or -silenced prostate cancer cells. Cells were grown on glass coverslips, fixed and stained with Alexa Fluor 488–conjugated phalloidin. Cells were then analyzed and photographed using fluorescent microscope. Myb-overexpressing (LNCaP-Myb and C4-2-Scr) cells exhibited several filopodial and lamellipodia-like projections (white arrows) as compared with low Myb–expressing (LNCaP-Neo and C4-2-shMyb) cells. (B) Expression profiles of various epithelial (E-cadherin) and mesenchymal markers (N-cadherin, Vimentin, Slug, Snail and Twist) were examined in Myb-overexpressing or -silenced cells by immunoblot analyses. Myb overexpression was associated with loss of epithelial and gain of mesenchymal markers, indicating its role in EMT.
In summary, we have provided evidence for a functional role of Myb in growth, androgen deprivation–resistance and malignant behavior of the prostate cancer cells. These are important observations suggesting that Myb could be developed as a marker for predicting the response to hormone therapy and should provide the impetus for future studies on prognostic and therapeutic assessments of Myb in prostate cancer.

Funding

National Institute of Health (NIH)/National Cancer Institute (NCI) (CA137513); Department of Defense (DOD)/US Army (W81XWH-09-1-0137); University of South Alabama Mitchell Cancer Institute (USAMCI).

Conflict of Interest Statement: None declared.

References

20. Lidonnici,M.R. et al. (2008) Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogene-

27. Cheng,H. et al. (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor pro-


Received January 24, 2012; revised February 29, 2012; accepted March 14, 2012